The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Latamoxef     (6R,7R)-7-[[2-carboxy-2-(4...

Synonyms: Shiomarin, Festamoxin, Lamoxactam, moxalactam, Lilly 127935, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of moxalactam


High impact information on moxalactam


Chemical compound and disease context of moxalactam


Biological context of moxalactam


Anatomical context of moxalactam


Associations of moxalactam with other chemical compounds


Gene context of moxalactam


Analytical, diagnostic and therapeutic context of moxalactam


  1. Temocillin. In vitro antibacterial activity. Slocombe, B., Cooper, C.E., Griffin, K.E., White, A.R. Drugs (1985) [Pubmed]
  2. In vitro activity of cefotaxime against clinically significant pathogens. Nakashio, S., Nakamura, M. Drugs (1988) [Pubmed]
  3. 'Covalent trapping' and latamoxef resistance in beta-lactamase-derepressed Pseudomonas aeruginosa. Livermore, D.M. J. Antimicrob. Chemother. (1987) [Pubmed]
  4. Phosphate deprivation is associated with high resistance to latamoxef of gel-entrapped, sessile-like Escherichia coli cells. Vilain, S., Cosette, P., Junter, G.A., Jouenne, T. J. Antimicrob. Chemother. (2002) [Pubmed]
  5. In-vitro activity of FCE 22101 and other beta-lactam antibiotics against Enterobacteriaceae resistant to third generation cephalosporins. Jarlier, V., Nicolas, M.H., Philippon, A., Giroir, A.M., Grosset, J. J. Antimicrob. Chemother. (1989) [Pubmed]
  6. A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans. Yamamoto, T., Yasuda, J., Kanao, M., Okada, H., Oguma, T., Yamada, H. Clinical pharmacokinetics. (1986) [Pubmed]
  7. In-vitro evaluation of beta-lactamase inhibition by latamoxef and imipenem. Sotto, A., Brunschwig, C., O'Callaghan, D., Ramuz, M., Jourdan, J. J. Antimicrob. Chemother. (1996) [Pubmed]
  8. Different mechanisms of resistance to latamoxef (moxalactam) in Serratia marcescens. Gutmann, L., Chabbert, Y.A. J. Antimicrob. Chemother. (1984) [Pubmed]
  9. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics. Jacobus, N.V., Tally, F.P., Gorbach, S.L. J. Antimicrob. Chemother. (1985) [Pubmed]
  10. Imipenem therapy of Pseudomonas aeruginosa bacteraemia in neutropenic rats. Johnson, D.E., Calia, F.M., Snyder, M.J., Warren, J.W., Schimpff, S.C. J. Antimicrob. Chemother. (1983) [Pubmed]
  11. Evaluation of aztreonam, cefoperazone, latamoxef and ceftazidime in the hamster colitis model. Weinberg, D.S., Fernandes, P.B., Kao, C.C., Clark, J.M., Bonner, D.P., Sykes, R.B. J. Antimicrob. Chemother. (1986) [Pubmed]
  12. In-vitro activity and beta-lactamase stability and inhibitory properties of a new penem antibiotic, Sch 34343. Neu, H.C., Chin, N.X., Labthavikul, P. J. Antimicrob. Chemother. (1985) [Pubmed]
  13. Latamoxef: single agent prophylaxis in colorectal surgery. Thomas, W.E., Cooper, M.J., Holt, A., Reeves, D. J. Antimicrob. Chemother. (1985) [Pubmed]
  14. The effects of latamoxef, cefotaxime, and cefoperazone on platelet function and coagulation in normal volunteers. Weitekamp, M.R., Caputo, G.M., Al-Mondhiry, H.A., Aber, R.C. J. Antimicrob. Chemother. (1985) [Pubmed]
  15. Trapping and hydrolysis of latamoxef by beta-lactamase in Pseudomonas aeruginosa. Livermore, D.M. J. Antimicrob. Chemother. (1989) [Pubmed]
  16. Alterations of pharmacokinetic properties of gentamicin, penicillin G and two cephalosporins in septicaemic rabbits. Haslberger, A.G., Ganzinger, U., Reiter, H., Schiel, H., Millendorfer, A. J. Antimicrob. Chemother. (1987) [Pubmed]
  17. Outer membrane proteins responsible for the penetration of beta-lactams and quinolones in Pseudomonas aeruginosa. Yamano, Y., Nishikawa, T., Komatsu, Y. J. Antimicrob. Chemother. (1990) [Pubmed]
  18. The penetration of latamoxef disodium (moxalactam) into the subcutaneous fat and skeletal muscle of ischaemic lower limbs with atherosclerotic disease. Stewart, J., Courtney, D.F., Fowler, B., Ramsden, C.H., Kester, R.C. J. Antimicrob. Chemother. (1984) [Pubmed]
  19. The concentration of latamoxef achieved in the bile and gallbladder wall of patients with cholecystitis. Vowden, P., Stewart, J., Fowler, B., Ramsden, C.H., Kester, R.C. J. Antimicrob. Chemother. (1986) [Pubmed]
  20. Influence of three modes of administration on the penetration of latamoxef into interstitial fluid and fibrin clots and its in-vivo activity against Haemophilus influenzae. Bergeron, M.G., Simard, P. J. Antimicrob. Chemother. (1986) [Pubmed]
  21. Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours. Oturai, P.S., Holländer, N.H., Hansen, O.P., Boas, J., Bruun, B.G., Frimodt-Møller, N., Dombernowsky, P., Hansen, H.H. Eur. J. Cancer (1993) [Pubmed]
  22. Broad-spectrum beta-lactam resistance in Enterobacter: emergence during treatment and mechanisms of resistance. Olson, B., Weinstein, R.A., Nathan, C., Kabins, S.A. J. Antimicrob. Chemother. (1983) [Pubmed]
  23. Single-dose prophylaxis in elective colorectal surgery: a prospective, randomized trial with piperacillin or latamoxef. Reers, B., Winde, G., Sulkowski, U., Blum, M. Journal of chemotherapy (Florence, Italy) (1989) [Pubmed]
  24. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (4). Effects of tobramycin alone and in combination with latamoxef on the stability of rat kidney lysosomal membranes. Kojima, R., Ito, M., Suzuki, Y. Jpn. J. Pharmacol. (1987) [Pubmed]
  25. Beta-lactamase stability and antibacterial activity of cefpirome alone and in combination with other antibiotics. Bakhtiar, M., Selwyn, S. Drugs under experimental and clinical research. (1989) [Pubmed]
  26. Binding of latamoxef (moxalactam) and its decarboxylated derivative to Escherichia coli and Pseudomonas aeruginosa penicillin-binding proteins. Labia, R., Baron, P., Masson, J.M. J. Antimicrob. Chemother. (1985) [Pubmed]
  27. Mortality rate and bacteremia, endotoxin, and endothelin-1 levels in antibiotic therapy for E. coli septic peritonitis. Tsukada, K., Katoh, H., Shiojima, M., Takenoshita, S., Nagamachi, Y. APMIS (1993) [Pubmed]
  28. Treatment failures of cefotaxime and latamoxef in meningitis caused by Enterobacter and Serratia spp. Eng, R.H., Cherubin, C.E., Pechere, J.C., Beam, T.R. J. Antimicrob. Chemother. (1987) [Pubmed]
  29. Comparison of rapid bacteriological response to MT-141 and latamoxef in complicated urinary tract infections. Miyamoto, S., Tamiya, T., Takatsuka, K., Kumamoto, Y. Drugs under experimental and clinical research. (1985) [Pubmed]
WikiGenes - Universities